Parabilis Medicines Q2 2026 Financial Results and Updates
Biotechnology
Earnings
IPO:
Jun 10, 2026
Industry:
PHARMACEUTICAL PREPARATIONS
Show Chart?
Load external content from TradingView!
*You can change or withdraw your consent at any time in the footer under Cookies.
Parabilis Medicines Reports Second Quarter 2026 Financial Results and Business Updates
CAMBRIDGE, Mass., USA - Parabilis Medicines (Nasdaq: PBLS) reported its financial results for the second quarter ended June 30, 2026, alongside key business updates, highlighted by progress with its lead candidate zolucatetide and a strategic collaboration with Regeneron.
... Read on — Members only
About Parabilis Medicines, Inc.
We are a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease. We leverage our proprietary platform to pioneer a novel therapeutic modality, Helicons, which are stabilized helical peptides engineered to bind and precisely modulate proteins that have long been beyond the reach of conventional medicines.
